The Daily Fuckup

President Donald Trump signed an executive order on April 18 directing federal agencies to move faster on investigational psychedelic drugs for serious mental illness, including ibogaine compounds. The order does not legalize psychedelics, and it does not approve any of them for general use. Instead, it tries to push the existing regulatory machinery to work faster for products already in the pipeline. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/))

The order tells the Food and Drug Administration commissioner to give Commissioner’s National Priority Vouchers to psychedelic drugs that have already received Breakthrough Therapy designation and qualify under the voucher program. It also tells the FDA and the Drug Enforcement Administration to set up a pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds, under the Right to Try Act and any needed controlled-substances handling permissions. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/))

The administration is also putting $50 million from existing funds into the effort through the Advanced Research Projects Agency for Health. According to the White House, the money is meant to match state investments in psychedelic research programs for people with serious mental illness. That is targeted funding, not a nationwide coverage mandate or a new federal benefit. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/))

The order also pushes coordination across federal health agencies, the Department of Veterans Affairs, and the private sector to expand clinical trial participation and data sharing. It directs the attorney general to begin reviews of relevant products after successful Phase 3 trials so rescheduling can move quickly if a drug is later approved. That is a process step, not a blanket scheduling change or an approval by itself. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/))

Politically, the White House is selling the move as a way to give patients with treatment-resistant conditions more options. Legally, the boundaries stay in place: the drugs remain controlled, the access path is limited, and any broader shift still depends on the FDA, DEA, HHS, and whatever follows from later clinical data and agency action. ([whitehouse.gov](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/))